CTSC and bronchiectasis: Based on the critical role of neutrophil elastase in bronchiectasis, bresocatib, a selective and reversible inhibitor of dipeptidyl peptidase 1 that inhibits neutrophil elastase activity, was developed as an effective new drug for the treatment of bronchiectasis [23].